Breaking: UBS Reconfirms $120 PT On Celgene (NASDAQ:CELG) Shares, Reconfirms Their Original “Buy” Rating

November 7, 2017 - By Kurt Siggers

 Breaking: UBS Reconfirms $120 PT On Celgene (NASDAQ:CELG) Shares, Reconfirms Their Original

Investors sentiment increased to 1.34 in 2017 Q2. Its up 0.21, from 1.13 in 2017Q1. It improved, as 60 investors sold Celgene Corporation shares while 390 reduced holdings. 110 funds opened positions while 494 raised stakes. 602.51 million shares or 1.81% more from 591.78 million shares in 2017Q1 were reported.

Jackson Square Prtn Ltd Liability Co holds 4.76% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 7.17 million shares. Ledyard Bancorporation holds 0.04% or 2,106 shares. Ferguson Wellman Capital holds 0.02% or 5,112 shares. Gibraltar Capital Mgmt holds 3.92% or 30,206 shares in its portfolio. Ngam L P reported 227,231 shares. Wedgewood Investors Pa stated it has 0.28% in Celgene Corporation (NASDAQ:CELG). First Trust Advsrs L P holds 0.18% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 521,593 shares. Philadelphia owns 44,956 shares for 0.5% of their portfolio. Cs Mckee Limited Partnership stated it has 190,950 shares. Los Angeles Cap Management Equity reported 135,460 shares. North Star Investment Management reported 27,260 shares. Arizona-based Arizona State Retirement has invested 0.35% in Celgene Corporation (NASDAQ:CELG). Lsv Asset Management accumulated 13,100 shares or 0% of the stock. Mogy Joel R Inv Counsel holds 18,605 shares. Hall Laurie J Trustee has invested 0% in Celgene Corporation (NASDAQ:CELG).

Since June 15, 2017, it had 0 buys, and 3 insider sales for $2.36 million activity. Shares for $1.16M were sold by CASEY MICHAEL D on Saturday, June 17. $575,038 worth of Celgene Corporation (NASDAQ:CELG) was sold by VESSEY RUPERT on Thursday, June 15.

Celgene (NASDAQ:CELG) Rating Reaffirmed

UBS now has a $120 price target on the $80.15 billion market cap company or 17.88 % upside potential. In an analyst note shared with investors and clients on Friday, 27 October, Celgene (NASDAQ:CELG) shares have had their “Buy” Rating maintained by research analysts at UBS.

Investors sentiment increased to 1.34 in 2017 Q2. Its up 0.21, from 1.13 in 2017Q1. It improved, as 60 investors sold Celgene Corporation shares while 390 reduced holdings. 110 funds opened positions while 494 raised stakes. 602.51 million shares or 1.81% more from 591.78 million shares in 2017Q1 were reported.

Jackson Square Prtn Ltd Liability Co holds 4.76% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 7.17 million shares. Ledyard Bancorporation holds 0.04% or 2,106 shares. Ferguson Wellman Capital holds 0.02% or 5,112 shares. Gibraltar Capital Mgmt holds 3.92% or 30,206 shares in its portfolio. Ngam L P reported 227,231 shares. Wedgewood Investors Pa stated it has 0.28% in Celgene Corporation (NASDAQ:CELG). First Trust Advsrs L P holds 0.18% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 521,593 shares. Philadelphia owns 44,956 shares for 0.5% of their portfolio. Cs Mckee Limited Partnership stated it has 190,950 shares. Los Angeles Cap Management Equity reported 135,460 shares. North Star Investment Management reported 27,260 shares. Arizona-based Arizona State Retirement has invested 0.35% in Celgene Corporation (NASDAQ:CELG). Lsv Asset Management accumulated 13,100 shares or 0% of the stock. Mogy Joel R Inv Counsel holds 18,605 shares. Hall Laurie J Trustee has invested 0% in Celgene Corporation (NASDAQ:CELG).

Since June 15, 2017, it had 0 buys, and 3 insider sales for $2.36 million activity. Shares for $1.16M were sold by CASEY MICHAEL D on Saturday, June 17. $575,038 worth of Celgene Corporation (NASDAQ:CELG) was sold by VESSEY RUPERT on Thursday, June 15.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 31 analysts covering Celgene Corporation (NASDAQ:CELG), 20 have Buy rating, 2 Sell and 9 Hold. Therefore 65% are positive. Celgene Corporation has $190 highest and $83 lowest target. $139.50’s average target is 37.03% above currents $101.8 stock price. Celgene Corporation had 110 analyst reports since July 21, 2015 according to SRatingsIntel. SunTrust maintained Celgene Corporation (NASDAQ:CELG) on Friday, October 27 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Wednesday, October 5. The firm has “Outperform” rating given on Tuesday, October 17 by BMO Capital Markets. Mizuho maintained the stock with “Buy” rating in Thursday, June 1 report. On Monday, October 16 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Buy” rating given on Tuesday, September 26 by Cantor Fitzgerald. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. On Friday, June 30 the stock rating was downgraded by BTIG Research to “Neutral”. The stock has “Hold” rating by JMP Securities on Friday, October 27. The company was maintained on Friday, January 29 by RBC Capital Markets.

About 3.98 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since November 7, 2016 and is uptrending. It has outperformed by 0.30% the S&P500.

Celgene Corporation is an integrated global biopharmaceutical company. The company has market cap of $80.15 billion. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 23.98 P/E ratio. The Company’s commercial-stage products include REVLIMID , POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide).

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “Celgene’s Gilead Moment” on November 01, 2017, also Nasdaq.com with their article: “Celgene Corporation Bottom Line Climbs 24% In Q3” published on October 26, 2017, Fool.com published: “Celgene Corporation Has “Optionality and Opportunity”” on October 30, 2017. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “The Stumbling Blocks Of Celgene-Dependent Acceleron And Why You Should Hedge …” published on November 07, 2017 as well as Seekingalpha.com‘s news article titled: “Why Celgene Got Pummeled” with publication date: October 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.